Our results are consistent with a previous study on NSCLC patients in a Chinese population, which reports a higher percentage of EGFR mutations (56%) and a lower percentage of KRAS mutations (12%) (15). This evidence concerns the gene EGFR and non-small cell lung carcinoma.